Successful advancement of new drugs into clinical practice depends on reliable preclinical models. Having access to advanced, clinically relevant ex vivo models and assays for evaluating novel cancer therapeutics is essential. At Champions, our scientists have created a comprehensive suite of ex vivo assays, including the largest biobank of ex vivo blood cancer models, our proprietary TumorGraft3D platform for drug testing in multiclonal 3D-organoids, and a co-culture platform for preclinical screening of immuno-therapeutics.
Clinically Relevant Models
A diverse bank of ex vivo preclinical models that mirrors the oncology patient population
Pretreated Models for Research
The largest bank of ex vivo models pretreated with latest-generation targeted therapies
Multi-omic Characterization
Clinical annotations coupled with multi-omic molecular datasets and ex vivo responses
Your Oncology Research Partner
Delivering tailored consultations from scientists with Extensive Experience in Oncology
Champions Oncology provides a comprehensive suite of ex vivo services, designed for evaluating new cancer therapies across all modalities. Our platforms screen the therapeutic potential of your treatments to maximize success in vivo.
Test therapeutics in the largest bank of highly characterized primary, never-passaged hematological models from leukemia, lymphoma, & myeloma patients
Evaluate therapeutic efficacy in Champions' matrix-free, multiclonal 3D ex-vivo culture established from unique PDX models
Assess the effect therapeutic agents have on cancer cells and the immune system in the tumor microenvironment
___________________________________________________
___________________________________________________
___________________________________________________
Ex vivo tumor models are generated from tumor tissues or cells from patients or animal models and used shortly after their collection to minimize the adaptation to culture conditions and selection processes that are typically observed in models grown in vitro. to study cancer outside the organism. Ex vivo models from solid tumors can be developed as two-dimensional (2D) cultures in adherent plates or as three-dimensional (3D) cultures in suspension in non-adherent plates in presence or absence of an extracellular matrix. Ex vivo models of hematopoietic malignancies are grown as cell suspensions from samples collected from blood or bone marrow.
At Champions, we provide a range of ex vivo solutions tailored to diverse project needs:
Ex vivo models are important experimental tools that bridge the gap between in vitro cell cultures and in vivo animal models, they help improve drug development by providing a more accurate representation of how a drug might perform by offering a more physiologically relevant substrate for evaluation of the efficacy of potential cancer therapies. Ex vivo models enable faster, cost-effective, and higher-throughput assessment of therapeutic agent’s efficacy or mechanism of action, and enable informed decision-making when transitioning into in vivo studies.
There are many aspects to be considered when planning and executing a successful ex vivo study. Champions works with you every step of the way to ensure you select the best models to test your hypothesis and choose endpoints that will lead to unparalleled insights driving decision-making.
